8-K Announcements
6Material company update
Feb 10, 2026·SEC
Material company update
Dec 29, 2025·SEC
Material company update
Nov 5, 2025·SEC
Dynavax Technologies Corporation(DVAX)Earnings, Financials & Key Ratios
DVAX•NASDAQ
$15.50
77.5× P/E·Price updated Jun 20, 2026
AboutDynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.Show more
- Revenue$277M+19.4%
- EBITDA$4M+113.2%
- Net Income$27M+527.4%
- EPS (Diluted)0.20+503.2%
- Gross Margin82.17%+4.8%
- EBITDA Margin1.42%+111.1%
- Operating Margin-1.49%+90.7%
- Net Margin9.85%+458.1%
- ROE4.48%+521.9%
DVAX Price & Volume
Dynavax Technologies Corporation (DVAX) stock price & volume — 10-year historical chart
Loading chart...
HEPLISAV-B Commercial Scaling Drives Operational Margin Recovery
Investment Thesis • Updated 2025Q3
VerdictNeutral
Growth:Expanding
Profitability:Moderate
Financial:Healthy
Cash Flow:Improving
Primary Risk:Pipeline diversification execution risk
Key Thesis Takeaways
- Dynavax is successfully transitioning from pandemic-era adjuvant volatility to a sustainable commercial model anchored by the HEPLISAV-B vaccine franchise.
- While the company demonstrates improved operating leverage and a robust 84.8% gross margin as of 2025Q3, investors should monitor the impact of $12.4M in quarterly stock-based compensation on true earnings quality.
- Long-term value remains contingent on the firm's ability to defend its market position against emerging mRNA-based platforms while managing the capital intensity reflected in its $953.7M accumulated deficit.
Verdict Logic
while the company achieved a 22.4% operating margin in 2025Q3, the high P/E ratio of 77.50 warrants caution regarding the sustainability of current valuation levels relative to long-term competitive risks.
DVAX Growth Metrics
Dynavax Technologies Corporation (DVAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years38.05%
5 Years51.08%
3 Years-14.23%
TTM26.73%
Profit CAGR
10 Years-
5 Years-
3 Years-29.13%
TTM-311.94%
EPS CAGR
10 Years-
5 Years-
3 Years-29.47%
TTM-395.34%
Return on Capital
10 Years-32.07%
5 Years8.77%
3 Years12.79%
Last Year-0.45%
DVAX Recent Earnings
Dynavax Technologies Corporation (DVAX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 7/12 qtrs (64%)
Q1 2026Latest
Feb 19, 2026Metric
Actual
Est
EPS
$0.05-38.5%
$0.08
Rev
—
$82M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.21+50.0%
$0.14
Rev
$95M+18.2%
$80M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.14+16.7%
$0.12
Rev
$95M+1.5%
$94M
Q2 2025
May 6, 2025Metric
Actual
Est
EPS
$0.11-466.7%
$0.03
Rev
$68M-19.0%
$84M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 19, 2026 | $0.05vs $0.08-38.5% | —vs $82M |
| Q4 2025 | Nov 5, 2025 | $0.21vs $0.14+50.0% | $95Mvs $80M+18.2% |
| Q3 2025 | Aug 7, 2025 | $0.14vs $0.12+16.7% | $95Mvs $94M+1.5% |
| Q2 2025 | May 6, 2025 | $0.11vs $0.03-466.7% | $68Mvs $84M-19.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Dynavax Technologies Corporation (DVAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.50 | $1.82B | 77.50 | 19.36% | 9.85% | 4.48% | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — | |
| $3.67 | $263.23M | 11.12 | -31.8% | 21.61% | 10.62% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $0.55 | $133.16M | 7.86 | 726.68% | 14.51% | 61.43% | — | |
| $8.76 | $9.17B | -23.05 | 668.31% | -606.15% | — | — |
Compare DVAX vs Peers
Dynavax Technologies Corporation (DVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DVAX SEC Filings & Documents
Dynavax Technologies Corporation (DVAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when DVAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DVAX Frequently Asked Questions
Dynavax Technologies Corporation (DVAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Dynavax Technologies Corporation's revenue?
Dynavax Technologies Corporation (DVAX) reported $330.5M in revenue for fiscal year 2024. This represents a 23061% increase from $1.4M in 2002.
How fast is Dynavax Technologies Corporation growing?
Dynavax Technologies Corporation (DVAX) grew revenue by 19.4% over the past year. This is strong growth.
Is DVAX profitable?
Dynavax Technologies Corporation (DVAX) reported a net loss of $43.4M for fiscal year 2024.
Dividend & Returns
What is DVAX's return on equity?
Dynavax Technologies Corporation (DVAX) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.
What is Dynavax Technologies Corporation's free cash flow?
Dynavax Technologies Corporation (DVAX) generated $80.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.